Bcr-Abl
Los inhibidores de Bcr-Abl son terapias dirigidas que inhiben la proteína de fusión Bcr-Abl, formada debido a la translocación del cromosoma Filadelfia y que es un impulsor de la leucemia mieloide crónica (LMC). Esta proteína también influye en la angiogénesis, contribuyendo a la progresión tumoral. Los inhibidores de Bcr-Abl son cruciales en el tratamiento de la LMC y se están explorando por su potencial para inhibir la angiogénesis en varios tipos de cáncer. En CymitQuimica, ofrecemos inhibidores de Bcr-Abl de alta calidad para apoyar su investigación en biología del cáncer, angiogénesis y terapias dirigidas.
Se han encontrado 102 productos de "Bcr-Abl"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Bosutinib
CAS:<p>Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.</p>Fórmula:C26H29Cl2N5O3Pureza:98.98% - 99.9%Forma y color:Yellowish-Orange Or Pink To Brownish Solid Solid PowderPeso molecular:530.45Dasatinib monohydrate
CAS:<p>Dasatinib monohydrate, an oral SRC-kinase inhibitor, counters imatinib-resistant chronic myeloid leukemia.</p>Fórmula:C22H28ClN7O3SPureza:99.68% - >99.99%Forma y color:SolidPeso molecular:506.03Nilotinib
CAS:<p>Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.</p>Fórmula:C28H22F3N7OPureza:99.89% - >99.99%Forma y color:Off-White SolidPeso molecular:529.52Imatinib Mesylate
CAS:<p>Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,</p>Fórmula:C29H31N7O·CH4SO3Pureza:98% - >99.99%Forma y color:White Crystalline PowderPeso molecular:589.71LXH254
CAS:<p>LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.</p>Fórmula:C25H25F3N4O4Pureza:98.3% - 99.92%Forma y color:SolidPeso molecular:502.49N-Desmethyl imatinib
CAS:<p>N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.</p>Fórmula:C28H29N7OPureza:98.60%Forma y color:Off-White To Pale-Yellow SolidPeso molecular:479.58Dasatinib
CAS:<p>Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive.</p>Fórmula:C22H26ClN7O2SPureza:99.59% - 99.86%Forma y color:Pale-Yellow SolidPeso molecular:488.01Lyn-IN-1
CAS:<p>Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and Lyn</p>Fórmula:C30H31F3N8OPureza:97% - 98.02%Forma y color:SolidPeso molecular:576.62AKE-72
CAS:<p>AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.</p>Fórmula:C30H29F3N6OPureza:98.3%Forma y color:SoildPeso molecular:546.59SNIPER(ABL)-015
<p>SNIPER(ABL)-015, a compound that conjugates GNF5 (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels with a DC50 of 5</p>Fórmula:C58H70F3N9O9Pureza:98%Forma y color:SolidPeso molecular:1094.23ML 2-23
<p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>Fórmula:C47H53BrCl2N10O7SPureza:98%Forma y color:SolidPeso molecular:1052.86PROTAC BCR-ABL Degrader-1
<p>PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway and</p>Fórmula:C43H40N10O6Pureza:98%Forma y color:SolidPeso molecular:792.84FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Forma y color:LiquidDPH
CAS:<p>DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.</p>Fórmula:C18H13FN4O2Pureza:99.65%Forma y color:SolidPeso molecular:336.32SNIPER(ABL)-050
<p>SNIPER(ABL)-050 is a chemical compound that combines Imatinib, an ABL inhibitor, with MV-1, an IAP ligand, using a linker.</p>Fórmula:C68H84N12O9Pureza:98%Forma y color:SolidPeso molecular:1213.47SNIPER(ABL)-058
CAS:<p>SNIPER(ABL)-058, a compound that links Imatinib (ABL inhibitor) with a derivative of LCL161 (IAP ligand) through a linker, effectively decreases BCR-ABL protein</p>Fórmula:C62H75N11O9SPureza:98%Forma y color:SolidPeso molecular:1150.39SNIPER(ABL)-047
<p>SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,</p>Fórmula:C67H82F3N11O9SPureza:98%Forma y color:SolidPeso molecular:1274.5Abl Cytosolic Substrate
CAS:<p>Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).</p>Fórmula:C64H101N15O16Pureza:98%Forma y color:SolidPeso molecular:1336.58FGFRs-IN-1
<p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>Fórmula:C28H26Cl2N4O3Forma y color:SolidPeso molecular:537.44PROTAC BCR-ABL1 ligand 1
CAS:<p>GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.</p>Fórmula:C17H12F3N3O2Forma y color:SoildPeso molecular:347.29
